Trial Profile

Randomed and Double-blinded Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hydronidone (Primary) ; Entecavir
Indications Hepatic fibrosis
Focus Therapeutic Use
Sponsors Shanghai Genomics

Most Recent Events

17 Aug 2020 According to a GNI media release, more detailed results and the final report of the study will be published later at medical conferences and/or medical journals in the future.
17 Aug 2020 Primary endpoint has been met. (Changes in hepatic fibrosis in chronic viral hepatitis B), according to a GNI Media Release.
17 Aug 2020 Positive results from the initial analysis published in the GNI Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com